CapsoVision to Participate in the 38th Annual ROTH Conference
Rhea-AI Summary
CapsoVision (NASDAQ: CV) will present at the 38th Annual ROTH Conference on Monday, March 23, 2026 in Dana Point, CA. Management will host a fireside chat and hold 1x1 investor meetings at 10:30–10:55 am PT.
The fireside chat will be webcast live and archived on the company Events page for one year; investors can request one-on-one meetings via their Roth representative or Investors@CapsoVision.com.
Positive
- None.
Negative
- None.
News Market Reaction – CV
In the Mar 10 session, CV gained 1.76%, reflecting a mild positive market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Dec 29 | AI 510(k) submission | Positive | +7.0% | Filed 510(k) for AI-assisted reading module for CapsoCam Plus system. |
| Nov 20 | Investor conference | Neutral | -1.9% | Announced participation in Benchmark one-on-one investor conference. |
| Nov 13 | Q3 2025 earnings | Negative | -9.7% | Higher Q3 revenue but continued losses and going-concern language disclosed. |
| Nov 10 | BDD application | Positive | +10.2% | Submitted FDA Breakthrough Device Designation application for pancreatic screening capsule. |
| Nov 03 | Finance SVP hire | Positive | -2.0% | Appointed David Garcia as Senior Vice President of Finance. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
News tied to regulatory or technology milestones (510(k), Breakthrough Device) has often coincided with positive moves, while earnings and some corporate updates have seen negative reactions.
Over the last six months, CapsoVision reported several milestones, including an AI-assisted reading module 510(k) submission on Dec 29, 2025 and a Breakthrough Device Designation application on Nov 6, 2025, both followed by double-digit or high-single-digit gains. By contrast, Q3 2025 earnings on Nov 13, 2025 showed higher revenue but ongoing losses and drew a near -10% reaction. Multiple investor conferences and a finance leadership appointment round out a pattern of active investor outreach alongside clinical and AI development.
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Company to participate in a fireside chat and 1x1 investor meetings on March 23, 2026 -
SARATOGA, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company developing advanced imaging and AI-enabled capsule endoscopy solutions, today announced that Johnny Wang, President and Chief Executive Officer, David Garcia, Senior Vice President of Finance, and Doug Atkinson, Senior Vice President of Global Sales, will participate in the 38th Annual ROTH Conference on Monday, March 23, 2026 in Dana Point, CA.
Format: Fireside Chat and 1x1 Investor Meetings
Date/Time: Monday, March 23, 2026, at 10:30–10:55 am PT
The fireside chat will be webcast live and archived on the Events page in the investor relations section of the company’s website for one year. If you are interested in arranging a one-on-one meeting with CapsoVision’s management team at the conference, please contact your Roth representative or reach out to the company directly at Investors@CapsoVision.com.
About CapsoVision
CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and diagnosis of gastrointestinal diseases. Its flagship product, CapsoCam Plus®, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company’s next pipeline product, CapsoCam Colon™ with enhanced AI, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit www.capsovision.com.
Investor Relations Contact
Leigh Salvo
New Street Investor Relations
Investors@CapsoVision.com
Media Contact
Leslie Strickler and Paul Spicer
Être Communications
leslies@etrecommunications.com | (804) 240-0807
pauls@etrecommunications.com | (804) 503-9231
